Import/Export Controls on Peptide Research Chemicals: Enforcement Update May 2026

The Enforcement Landscape Context

The import and export control environment for peptide-related products has become materially more complex in 2026 as enforcement agencies respond to several converging issues:

Illicit peptide trade growth: The consumer market for unregulated peptide products, growth hormone secretagogues, melanotan analogs, BPC-157, and other "research chemicals", has grown substantially, with a significant portion of supply originating from overseas manufacturers (primarily China) and entering the US through e-commerce and direct mail channels.

Compounding precursor control: FDA's enforcement posture on compounded GLP-1 products has elevated attention to APIs entering the US for compounding use outside of approved import channels.

National security dimensions: Some peptide research programs touch on dual-use science (peptide toxins, biodefense research) that implicates export control frameworks beyond pharmaceutical regulations.

Supply chain transparency: FDA has emphasized Active Pharmaceutical Ingredient (API) supply chain transparency in its drug supply security agenda, driving more rigorous scrutiny of pharmaceutical ingredient imports.

CBP Import Enforcement: What Has Changed

Increased Inspection Rates

CBP has expanded its flagging criteria for peptide-related shipments. Shipments that now face elevated inspection probability include:

• Peptide drug substances imported under research or investigational exemptions (FDA Form 2877 required)
• Peptide raw materials from manufacturers not on FDA's approved API manufacturer database
• Shipments with declared values inconsistent with known commercial pricing for legitimate peptide API (suggesting either undervaluation for duty purposes or non-pharmaceutical quality)
• Shipments from e-commerce platforms without an identified US importer of record

Documentation Requirements for Legitimate Importers

Pharmaceutical companies, CDMOs, and research institutions importing peptide APIs for legitimate purposes are encountering increased documentation requirements:

• Letter of authorization: Required from the US pharmaceutical company for imports of peptide APIs on behalf of that company
• GMP certification: Current GMP certification from the manufacturing site for pharmaceutical API imports
• Certificate of Analysis: Required at entry for pharmaceutical ingredient imports, reviewed against the declared specification
• FDA drug establishment registration: Confirmed registration of the foreign manufacturing site in FDA's drug establishment database

When documentation is incomplete, shipments may be detained for FDA review, typically adding 7-14 days to clearance time and requiring engagement with FDA's Import Operations staff.

Pharmaceutical importers should implement pre-import documentation verification protocols with foreign suppliers, confirming that all required documents will accompany the shipment before it departs the country of origin. Retroactive documentation assembly while a shipment is detained adds cost and delays. For research institutions importing peptide compounds for academic research, engagement with the university's research compliance office before placing international orders can prevent customs complications that disrupt research timelines.

FDA Import Alert Actions in 2026

FDA's import alert system allows automatic detention of shipments from manufacturers or distributors with documented compliance violations, without requiring case-by-case review. In 2026, FDA has added:

12 Chinese manufacturers to Import Alert 66-41 (unapproved new drugs) for peptide products including injectable BPC-157, TB-500, and other peptide products sold without FDA approval directly to US consumers through e-commerce.

3 Indian API manufacturers to Import Alert 66-40 for GMP violations identified during CGMP inspections, affecting peptide API shipments from those facilities until GMP issues are resolved and the import alert is withdrawn.

2 international distributors to Import Alert 57-01 for misbranded drug products, following investigations of peptide products labeled as "research use only" but marketed with drug claims.

Companies relying on API supply from foreign manufacturers should verify that their suppliers are not on FDA import alert before shipment, as import alert status is not always communicated proactively by suppliers.

DEA Scheduling Review: Peptide Analogs

The DEA is conducting a scheduling review of several peptide classes that have been identified as commercially available without controlled substance prescription requirements:

GHRP compounds (Ipamorelin, GHRP-2, GHRP-6, Hexarelin): These growth hormone releasing peptides act on ghrelin receptors and are used for growth hormone secretagogue effects. DEA is evaluating whether they warrant scheduling under the Controlled Substances Act's analog provisions or through formal scheduling rulemaking.

Melanotan peptide analogs: Melanotan-I (afamelanotide, which is approved as Scenesse for erythropoietic protoporphyria) and Melanotan-II (not approved in the US) are used illicitly for tanning and sexual function effects. DEA's review of Melanotan-II's scheduling status has advanced.

Selective Androgen Receptor Modulator (SARM) peptides: Some peptidic SARMs that do not fit cleanly under the anabolic steroid scheduling framework are under DEA review.

If scheduling actions proceed, import of these compounds, even for research purposes, would require DEA researcher registration and Schedule I/II import permits, creating significant burden for legitimate academic research programs.

Export Controls: Synthesis Technology

BIS has clarified its interpretation of Export Administration Regulations (EAR) as they apply to peptide synthesis equipment and software. The relevant developments:

Automated peptide synthesizers: High-throughput peptide synthesis platforms with certain technical parameters (throughput thresholds, integration with AI-driven sequence design) are being reviewed for export control classification. Companies exporting peptide synthesizers to countries on the Entity List or subject to export controls should obtain BIS guidance before completing sales.

Synthesis chemistry technology: Technical data and know-how related to certain advanced peptide synthesis approaches may require export license authorization for transfer to foreign nationals, even in academic settings (the "deemed export" issue in research collaborations).

Peptide toxin programs: Programs involving select agent peptide toxins (botulinum toxin, ricin, and related peptide toxins) are subject to CDC/USDA select agent regulations and ITAR/EAR controls as applicable, these have been long-standing requirements but enforcement attention has increased.

Staffing Implications: Regulatory Affairs and Trade Compliance

The intersection of pharmaceutical regulatory requirements and trade/customs law is creating demand for professionals who can navigate both domains:

Pharmaceutical trade compliance specialists, who understand both FDA import/export regulatory requirements and CBP customs procedures, are rare. Most regulatory affairs professionals have limited customs law expertise, and most trade compliance professionals have limited pharmaceutical regulatory expertise. Companies experiencing import enforcement issues often engage specialized outside counsel.

Import operations managers with pharmaceutical experience are being hired at CDMOs and pharmaceutical companies that rely on foreign API supply, as the increased inspection burden requires more intensive active management of the import process.

People Also Ask

What documentation is required to import peptide APIs into the United States?

Legitimate pharmaceutical peptide API imports require: a letter of authorization from the US sponsor/company, a current GMP certificate from the manufacturing site, a Certificate of Analysis for the specific lot, and confirmation that the manufacturing site is registered in FDA's Drug Establishment Registration database. FDA Form 2877 is required for imports under investigational or research exemptions. Incomplete documentation can result in CBP/FDA detention of the shipment.

How can I check if a foreign peptide API manufacturer is on FDA import alert?

FDA's import alert database is publicly available at the FDA website's Import Alert listing. Searching by manufacturer name, country, or product category will show whether a specific manufacturer or distributor has been placed on import alert and the basis for the alert. Pharmaceutical importers should conduct this verification as part of supplier qualification and before each import shipment from foreign manufacturers.

Are research peptides like BPC-157 and TB-500 controlled substances?

BPC-157 and TB-500 are not currently scheduled under the Controlled Substances Act. However, they are unapproved drug products under FDA's definition when marketed with therapeutic claims, making their import and distribution subject to FDA enforcement authority. FDA import alert actions in 2026 have targeted foreign manufacturers and distributors of these products sold to US consumers as "research chemicals" or supplements. DEA is reviewing the scheduling status of some peptide research chemicals, which could change their regulatory status.